InCarda Therapeutics, Inc.
InCarda Therapeutics is a biopharmaceutical company pioneering a novel approach of treating cardiovascular diseases and conditions by the inhalation route. The company focuses on transforming cardiovascular disease treatment through pulmonary delivery of established drugs, with a lead product in development for paroxysmal atrial fibrillation (PAF). They leverage known diseases, known drugs, and new delivery methods to reduce development risks and improve patient outcomes.
Industries
Nr. of Employees
small (1-50)
InCarda Therapeutics, Inc.
San Francisco, California
Patents
Kits and methods for induction of cardioversion in subjects with atrial arrhythmias
US-12059414-B2
View Details
Kits and methods for induction of cardioversion in subjects with atrial arrhythmias
US-12059414-B2
View DetailsProducts
Clinical-stage inhaled antiarrhythmic therapy for paroxysmal atrial fibrillation
A nebulized pulmonary formulation of a well‑established antiarrhythmic intended for rapid conversion of recent-onset paroxysmal atrial fibrillation, designed for rapid systemic delivery via the lungs and potential patient self-administration.
Clinical-stage inhaled antiarrhythmic therapy for paroxysmal atrial fibrillation
A nebulized pulmonary formulation of a well‑established antiarrhythmic intended for rapid conversion of recent-onset paroxysmal atrial fibrillation, designed for rapid systemic delivery via the lungs and potential patient self-administration.
Expertise Areas
- Inhalation drug delivery
- Clinical trial management (Phase 1–3)
- Cardiovascular therapeutics (antiarrhythmic development)
- Preclinical translational pharmacology
Key Technologies
- Pulmonary (inhalation) drug delivery
- Nebulization and breath-actuated nebulizers
- Intratracheal administration (preclinical)
- Inhalation formulation development
News & Updates
InCarda announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of inhaled flecainide in healthy volunteers, marking an important step in developing a rapid-onset treatment for recent onset atrial fibrillation.
InCarda raised over $5 million in a Series A financing to further develop its lead cardiovascular program for an inhaled therapy to treat paroxysmal atrial fibrillation.
The company announced the issuance of patents in the US, Australia, and Canada covering its lead product candidate, a novel inhaled formulation of flecainide for PAF.
InCarda announced the initiation of a Phase 1 clinical trial to evaluate the safety and tolerability of inhaled flecainide in healthy volunteers, marking an important step in developing a rapid-onset treatment for recent onset atrial fibrillation.
InCarda raised over $5 million in a Series A financing to further develop its lead cardiovascular program for an inhaled therapy to treat paroxysmal atrial fibrillation.
The company announced the issuance of patents in the US, Australia, and Canada covering its lead product candidate, a novel inhaled formulation of flecainide for PAF.